Lundbeck reports Phase IV Vyepti data

Stockholm-based Atrogi has reported positive human data for ATR-258, its first-in-class oral therapy designed to improve muscle function and body composition. Over eight weeks, treatment was associated with an approximately 13% improvement in lower-extremity muscle power, together with more lean mass and less fat mass.

Stockholm-based Mendus has presented updated five-year follow-up data from its completed ADVANCE II trial in acute myeloid leukemia (AML). It also gave an update on the ongoing VITAL-CML trial of its immunotherapy vididencel in chronic myeloid leukemia (CML). The data were presented at the Second Bologna Workshop on Immunotherapy for AML in Italy.

Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.

All planned patient visits have now been completed in the company's Phase III HEEALING1 study of linaprazan glurate in erosive GERD. Topline results are still expected in Q4 2026.

Long-term follow-up of the DiAPREV-IT trial shows that two subcutaneous injections of retogatein (GAD-alum) delayed progression to insulin-dependent, stage 3 type 1 diabetes by more than five years in a genetically defined subgroup of children.

Cereno Scientific has reported positive topline results from a Phase I pharmacokinetic (PK) bridging study of its HDAC inhibitor CS014. The results strengthen the company's plan to take the drug candidate directly into a Phase IIb trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD), without a Phase IIa trial or further non-clinical safety studies.

ResoTher Pharma has reported promising Phase 2a results for its cardioprotective drug candidate RTP-026, moving the company a step closer to a key efficacy trial and a potential pharma partnership or sale.